SAMSUNG PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,602 KRW | -0.62% |
|
-6.21% | -26.34% |
| Sales 2017 | 41.92B 30.43M | Sales 2018 | 46.48B 33.75M | Capitalization | 147B 107M |
|---|---|---|---|---|---|
| Net income 2017 | -7.54B -5.47M | Net income 2018 | -2.08B -1.51M | EV / Sales 2017 | 4.42 x |
| Net Debt 2017 | 18.71B 13.58M | Net cash position 2018 | 14.95B 10.86M | EV / Sales 2018 | 2.85 x |
| P/E ratio 2017 |
-21.3
x | P/E ratio 2018 |
-62.5
x | Employees | 240 |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 89.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.62% | ||
| 1 week | -6.21% | ||
| Current month | -11.39% | ||
| 1 month | -11.25% | ||
| 3 months | -27.51% | ||
| 6 months | -36.68% | ||
| Current year | -26.34% |
1 week
1 597.00
1 709.00
1 month
1 597.001 960.00
Current year
1 597.002 705.00
1 year
1 597.004 195.00
3 years
1 597.0012 350.00
5 years
1 597.0013 450.00
10 years
1 597.0021 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ki-Ho Kim
CEO | Chief Executive Officer | 57 | - |
Sang-Jae Kim
CEO | Chief Executive Officer | 57 | - |
Chang-Bum Woo
AUD | Comptroller/Controller/Auditor | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Woo-Jin Kim
BRD | Director/Board Member | 70 | - |
Sang-Jae Kim
CEO | Chief Executive Officer | 57 | - |
Gi-Woong Kim
BRD | Director/Board Member | 57 | 20-03-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 1,602 | -0.62% | 204,081 |
| 24-04-16 | 1,612 | -1.77% | 251,833 |
| 24-04-15 | 1,641 | -3.13% | 368,690 |
| 24-04-12 | 1,694 | +0.24% | 182,641 |
| 24-04-11 | 1,690 | -1.05% | 245,476 |
End-of-day quote Korea S.E., April 16, 2024
More quotes
SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.34% | 109M | |
| +20.40% | 44.1B | |
| +17.11% | 21.97B | |
| +8.10% | 13.27B | |
| +6.06% | 13.22B | |
| +35.95% | 11.36B | |
| -8.53% | 7.07B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.09% | 5.23B |
- Stock Market
- Equities
- A001360 Stock
